Please login to the form below

Not currently logged in

Antares hires Jonathan Jaffe as VP clinical development

His research experience includes time spent working on Novartis’ Zortress and Xolair

Antares Pharma has appointed Dr Jonathan Jaffe as its new VP of clinical development to head the company's progress in self-injection products and topical gel-based medicines.

Dr Jaffe has over 20 years industry and academic experience, during which time he has led global clinical development programmes and conducted all phases of research, for respiratory, transplant and autoimmune indications at Schering Plough Research Institute, Novartis, and Forest Research Institute.

Drugs that Dr Jaffe has worked on during his time as a researcher include Novartis' Zortress (everolimus) to prevent organ rejection after a transplant, and Genetech/Novartis' allergy medicine Xolair (omalizumab).

His most recent role was as a consultant in clinical programmes for Pharmanet-i3.

Before joining the industry at 1996 at Wyeth, Dr Jaffe spent the first 12 years of his career at several hospitals, public and universities across the US, including the laboratory of clinical investigation at the National Institutes of Health' allergy and infection diseases division.

“Jonathan's previous broad experience as a pharmaceutical clinician will be extremely valuable as we continue to execute on the development of our pipeline products,” said Dr Kaushik Dave, executive VP, product development.

3rd July 2012


Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...